−6.10USD
−535.98 MUSD
1.24 BUSD
88.26 M
About Sarepta Therapeutics, Inc.
Sector
CEO
Douglas S. Ingram
Headquarters
Cambridge
Website
Employees (FY)
1.31 K
Founded
1980
ISIN
US8036071004
FIGI
BBG000BCJ161
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where SRPT is featured.
Frequently Asked Questions
The current price of SRPT is 115.62 USD — it has decreased by 0.80% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sarepta Therapeutics, Inc. stocks are traded under the ticker SRPT.
Sarepta Therapeutics, Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
SRPT stock is 2.95% volatile and has beta coefficient of 0.24. Check out the list of the most volatile stocks — is Sarepta Therapeutics, Inc. there?
One year price forecast for Sarepta Therapeutics, Inc. has a max estimate of 224.00 USD and a min estimate of 128.00 USD.
SRPT earnings for the last quarter are −0.46 USD per share, whereas the estimation was −1.22 USD resulting in a 62.39% surprise. The estimated earnings for the next quarter are 0.07 USD per share. See more details about Sarepta Therapeutics, Inc. earnings.
Sarepta Therapeutics, Inc. revenue for the last quarter amounts to 331.82 M USD despite the estimated figure of 285.33 M USD. In the next quarter revenue is expected to reach 387.18 M USD.
Yes, you can track Sarepta Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
SRPT stock has fallen by 6.89% compared to the previous week, the month change is a 7.04% fall, over the last year Sarepta Therapeutics, Inc. has showed a 7.61% decrease.
SRPT net income for the last quarter is 45.66 M USD, while the quarter before that showed −40.94 M USD of net income which accounts for 211.53% change. Track more Sarepta Therapeutics, Inc. financial stats to get the full picture.
Today Sarepta Therapeutics, Inc. has the market capitalization of 10.94 B, it has decreased by 0.48% over the last week.
No, SRPT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, SRPT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sarepta Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 1.31 K employees. See our rating of the largest employees — is Sarepta Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sarepta Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sarepta Therapeutics, Inc. stock shows the buy signal. See more of Sarepta Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Sarepta Therapeutics, Inc. future price: according to them, SRPT price has a max estimate of 224.00 USD and a min estimate of 128.00 USD. Read a more detailed Sarepta Therapeutics, Inc. forecast: see what analysts think of Sarepta Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sarepta Therapeutics, Inc. EBITDA is −208.93 M USD, and current EBITDA margin is −16.80%. See more stats in Sarepta Therapeutics, Inc. financial statements.